Tier 3 — preclinical

The Impacts of Short-Term NMN Supplementation on Serum Metabolism, Fecal Microbiota, and Telomere Length in Pre-Aging Phase

Kai-Min Niu, Tongtong Bao, Lumin Gao, Meng Ru, Yumeng Li, Liang Jiang, Changming Ye, Shujin Wang, Xin Wu
Frontiers in Nutrition 2021 8:756243

Bibliography

PubMed
PMID 34912838
PubMed Central
PMC8667784
DOI
10.3389/fnut.2021.756243
Funding
Supported by the Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project, Hunan science and technology support, and Jiangxi provincial innovation/entrepreneurship support reported in the article.
Competing interests
Liang Jiang and Changming Ye were employees of ERA Biotechnology (Shenzhen) Co., Ltd.; the remaining authors reported no commercial or financial relationships that could be construed as a potential conflict.

Study snapshot

DesignSingle-arm human supplementation component embedded in a broader preclinical mouse metabolomics/microbiome study.
ModelEight human male volunteers aged 45–60 years; the paper also includes a separate pre-aging mouse experiment.
SampleHuman component: n=8.
InterventionOral NMN 300 mg/day in the human component.
Duration90 days in the human component, with PBMC telomere measurements over time.
EndpointsPBMC telomere length; Serial human telomere measurements; Preclinical serum metabolomics; Preclinical fecal microbiota

What the study showed, in plain terms

This paper combines preclinical mouse experiments with a very small uncontrolled human supplementation component. Eight men aged 45–60 took NMN and had peripheral-blood telomere length followed over time.

The human arm reported longer PBMC telomeres during supplementation. Because there was no placebo group and only eight participants, the result is best treated as an exploratory biomarker signal rather than evidence that NMN slows human aging.

Key findings

  • The human component reported an increase in PBMC telomere length during NMN supplementation.
  • The paper also reported extensive serum-metabolome and gut-microbiome changes in pre-aging mice, which should not be presented as human outcomes.
  • The uncontrolled human design prevents separating NMN effects from time, measurement variation, regression to the mean, or other factors.

What this study can and cannot tell us

The human sample was extremely small and consisted only of middle-aged men, with no placebo or concurrent control. The article combines animal and human data, so mechanistic mouse findings should not be generalized to the human volunteers. Telomere length is a biomarker rather than a clinical outcome.

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology